Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data

Date

21 Oct 2023

Session

Poster session 06

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Olivia Rohr

Citation

Annals of Oncology (2023) 34 (suppl_2): S1080-S1134. 10.1016/S0923-7534(23)01268-1

Authors

O. Rohr1, S. Priou2, G. Lamé2, G. Chatelier3, S. Babai4, S. Gallien5, R. Flicoteaux6, C. Tournigand1, E. Kempf1

Author affiliations

  • 1 Department Of Medical Oncology, Centre Hospitalier Universitaire Henri-Mondor Assistance Publique - Hopitaux De Paris, 94010 - Creteil/FR
  • 2 Industrial Engineering Research Department, CentraleSupélec - Paris-Saclay campus, 91192 - Gif sur Yvette/FR
  • 3 Department Of Medical Informatics, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, 75012 - Paris/FR
  • 4 Department Of Pharmacovigilance, Assistance Publique - Hopitaux De Paris, 75012 - Paris/FR
  • 5 Department Of Infectious Diseases, Centre Hospitalier Universitaire Henri-Mondor Assistance Publique - Hopitaux De Paris, 94010 - Creteil/FR
  • 6 Department Of Medical Information, Assistance Publique - Hopitaux De Paris, 75012 - Paris/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2080P

Background

ICIN is a major cause of death in cancer patients (pts). We aimed at identifying incidence of ICIN and predictors of poor prognosis in oncology.

Methods

We designed a multicenter retrospective cohort study on the Greater Paris University Hospitals' (APHP) clinical data warehouse. We included all adult pts with solid cancer hospitalized between January 2016 and December 2021 at APHP with an ICD-10 cancer code, with chemotherapy (chemo) within 30 days prior to the 1st ICIN (defined by the D70 or D611 ICD-10 codes AND a neutrophil count < 500/mm3). The primary outcome was the composite of Intensive Care Unit (ICU) hospitalization or death within 30 days. We collected cancer and chemo characteristics, use of G-CSF, Charlson score items and standard biological values.

Results

Among 141,586 cancer pts, 40,660 received chemo among whom 661 (1.6%) had ICIN. Their median age was 63 years (Interquartile Range (IQR) 54-70) and 330 (50%) were female. The median Charlson score was 10 (IQR 8-11). Documented bacterial or fungal infections were observed in 113 (17%) and 19 (3%) pts, respectively. Main primary cancers were lung (n= 204, 31%) and breast (n=87, 13%). Advanced cancers were present in 551 (83%) pts. The last chemo included platinum in 375 (57%) pts, 331 (50%) were in their 1st line of chemo and 284 (43%) in their 1st cycle of the current line, 149 (23%) had primary prophylactic G-CSF, 27 (4%) had a concomitant SarsCov2 infection. Primary outcome occurred in 120/661 (18%) pts: 57 (9%) were transferred to intensive care and 82 (12%) died within 30 days. After ICIN, 372 (56%) pts received subsequent chemo and 486 (74%) were able to return home. In a multivariate Cox model, higher monocyte count (HR 0.07; 95%CI 0.01-0.44) and albumin nadir (HR 0.93; 95%CI 0.91-0.96) decreased ICU hospitalization risk or death whereas both bacterial (HR 2.12; 95%CI 1.40-3.31) or fungal infection (HR 1.93; 95%CI 1.40-3.31) and concomitant Sars Cov2 infection (HR 2.93; 95%CI 1.41-6.33) increased it. Charlson index (HR: 1.00; 95%CI 0.91-1.10) and primary prophylactic G-CSF (HR 0.83; 95%CI 0.52-1.32) had no prognostic value.

Conclusions

Despite the use of primary prophylactic G-CSF, ICIN is an early event which leads to major complications.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Assistance Publique - Hôpitaux de Paris Cancer Group.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.